Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

NGX-4010 has the potential to receive a decision from the EMEA in the first half of 2009 and we anticipate the PDUFA date from the FDA for the NGX-4010 NDA to be in the second half of 2009. In preparation for the potential commercialization of NGX-4010 in Europe, we remain focused on securing a European commercialization partner. In the United States, while we remain confident that NGX-4010 for the management of pain associated with PHN can be launched effectively and efficiently using our own sales force targeting leading pain specialists, the current economic environment has prompted us to evaluate possible commercial partnerships for the potential U.S. launch of NGX-4010."

Third Quarter 2008 Financial Results

Total operating expenses for the third quarter of 2008 were approximately $6.3 million, including $373,000 of non-cash stock-based compensation expense, compared to approximately $9.5 million, including $389,000 of non-cash stock-based compensation expense, for the third quarter of 2007. The decrease in operating expenses was primarily attributed to lower costs associated with clinical studies of NGX-4010 as the Company had no large-scale clinical studies ongoing during the quarter. Partially offsetting lower clinical costs were increased internal regulatory expenses to support the submission of a new drug application for NGX-4010 in PHN with the FDA, increased expenses related to pre-commercialization activities for NGX-4010 and higher general and administrative expenses due to increased spending on general infrastructure and to support being a public company.

Net loss for the third quarter of 2008 was approximately $6.3 million, compared to a net loss of $9.2 million for the third quarter of 2007. Net loss per share attributable to common stockholders was $0.36 per share and $0.68 per share for the three months ended September 30, 2008 and 2007, respectively, based on weighted average shares outstanding of 17,538,886 and 13,429,471 res
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 SonaCare Medical, LLC, ... (HIFU) technology, announced that its Board of Directors ... Executive Officer, President and member of the Board ... will take-on expanded responsibilities within the company, including ... as overseeing commercialization, manufacturing and finance. , ...
(Date:10/25/2014)... YORK , Oct. 24, 2014 ... Inc. (ACCP), a biopharmaceutical company advancing patient care ... 1-for-50 reverse split of its common stock effective ... 24, 2014. PlasmaTech,s common stock will trade on ... and temporary ticker symbol "ACCPD". After 20 days, ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... October 21, 2014 The Americas ... inorganic refrigerants market in Americas with analysis and ... of the Americas Inorganic Refrigerants Market report, to ... This also provides a glimpse of the segmentation ... supported by various tables and figures. , ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3
... Comprehensive tutorials ... use these invaluable resources. , ... Seattle, WA (PRWEB) July 16, 2009 -- OpenHelix today announced the availability of new ... The dbGaP resource is a database of genotypes and phenotypes with extensive ...
... , PHILADELPHIA and LONDON, July 15 ... leading provider of biopharmaceutical institutional research. Thomson Reuters will incorporate Sagient,s assessments, ... Forecast Module of Thomson Pharma(R) Partnering ... Forecast Module , in beta testing now ...
... , BETHESDA, Md., July 15 The American Medical ... comments to the Office of the National Coordinator (ONC) and the ... The HIT Policy Committee and its Certification/Adoption Workgroup is meeting and ... , , Dr. Ted Shortliffe, ...
Cached Biology Technology:New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 2New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 3Thomson Reuters Partners With Sagient Research 2American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification 2
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
(Date:10/16/2014)... Although monocultures can be cultivated efficiently, they are ... water caused by monoculture cultivation is becoming increasingly ... principal crop form and are regarded as the ... production – quite wrongfully, finds Bernhard Schmid, an ... advocates a novel form of agriculture and forestry. ...
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... R. Rodney Howell, MD, FACMG, is the recipient of ... Achievement Award. Dr. Howell is Professor of Pediatrics and ... University of Miami. Dr. Howell, president of the American ... commitment and work in the field of pediatrics and genetic ...
... A new study has estimated that over 260,000 cats and dogs ... full year since the onset of the UK recession. ... of cats and dogs, currently being cared for by UK welfare ... capacity and the number entering these organisations during a 12-month period. ...
... On March 29, 2012, the National Science Foundation ... Coalition for National Science Funding and hosted by the ... Holt (NJ-12) and Judy Biggert (IL-13) and special guests ... "For 60 years, NSF has played a central ...
Cached Biology News:Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 2Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 3Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 4Are we really a nation of animal lovers? 2Science means innovation 2Science means innovation 3
Request Info...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD45RA TAC is designed to deplete human CD45RA from samples to isolate memory CD4+ or CD8+ T cells....
Biology Products: